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Abstract: Coronary artery disease (CAD) is the most prevalent form of cardiovascular disease affecting about 13 million 
Americans, while more than one million percutaneous transluminal intervention (PCI) procedures are performed annually 
in the USA. The relative high occurrence of restenosis, despite stent implementation, seems to be the primary limitation of 
PCI. Over the last decades, single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI), 
has proven an invaluable tool for the diagnosis of CAD and patients’ risk stratification, providing useful information 
regarding the decision about revascularization and is well suited to assess patients after intervention. Information gained 
from post-intervention MPI is crucial to differentiate patients with angina from those with exo-cardiac chest pain 
syndromes, to assess peri-intervention myocardial damage, to predict-detect restenosis after PCI, to detect CAD 
progression in non-revascularized vessels, to evaluate the effects of intervention if required for occupational reasons and 
to evaluate patients’ long-term prognosis. On the other hand, chest pain and exercise electrocardiography are largely 
unhelpful in identifying patients at risk after PCI. 
Although there are enough published data demonstrating the value of myocardial perfusion SPECT imaging in patients 
after PCI, there is still debate on whether or not these tests should be performed routinely.  
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INTRODUCTION 
  Coronary artery disease (CAD) is the most prevalent 
form of cardiovascular disease affecting millions of people 
all over the world and being a major public health problem. 
The impact of CAD on the health of individuals in the 
developed world has declined over the last decades due to 
the identification of modifiable risk factors and the 
introduction of new primary and secondary prevention 
strategies [1]. Revascularization procedures are routinely 
performed in patients with CAD. However, even with these 
improvements, the mortality rate is substantially higher than 
that in the general population.  
  Since 1979 when Gruentzing et al demonstrated the 
possibility of using percutaneous transluminal coronary 
angioplasty (PTCA) in patients with coronary artery disease 
(CAD), the method has been widely applied worldwide, 
despite the high restenosis rate of 20-65% in patients without 
stenting [2-4]. More recently, the introduction of intracoro-
nary stenting has induced a dramatic decline in acute 
complications and also a significant reduction of the 
restenosis rate to an average of 20-25% (below 10% with 
drug-eluting stents’ implementation). As a result, the use of 
and indications for percutaneous transluminal interventions 
(PCIs) have greatly expanded [5-9].  
  The development in nuclear myocardial perfusion 
imaging (MPI) has provided diagnostic and prognostic   
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implications in CAD patients, leading to an explosive 
increase in the performance of these studies. Specifically, in 
patients with CAD, MPI provides independent and 
incremental information in predicting future cardiac events, 
an essential step in choosing between medical management 
and revascularization. Variables that predict the likelihood of 
future events are the extent and severity of inducible 
ischemia, increased lung uptake of thallium, stress-induced 
ventricular dilatation and left ventricular ejection fraction 
(gated-SPECT studies) [10, 11].  
  Chest pain and exercise electrocardiography (ECG) are 
largely unhelpful in identifying patients at risk after PCI pro-
cedures. MPI is of proven value to assess patients post 
intervention.  
  MPI is performed either with thallium-201 (
201Tl) or 
technetium-99m (
99mTc) labeled compounds such as 
sestamibi and tetrofosmin, while single photon emission 
computed tomography (SPECT) has replaced planar imaging 
resulting in significant improvement of MPI scans [10, 11]. 
Moreover, the use of gated-SPECT provides the possibility 
to evaluate the left ventricular function parameters [10, 11].  
MPI AND PERCUTANEOUS CORONARY INTER-
VENTION  
  Currently, more than one million PCI procedures are 
performed annually in the U.S.A. [12].  Nowadays the 
method is routinely performed mainly in patients with acute 
myocardial infarction (MI) and unstable coronary syndro-
mes, and is increasingly employed to treat complex lesions, 
small-diameter vessels, chronic total occlusions, and SPECT Imaging After PCI  Current Cardiology Reviews, 2010, Vol. 6, No. 2    99 
diseased bypass conduits [1, 2]. In the mid 1990s, the publi-
cation of two multicenter trials which demonstrated impro-
ved outcomes, led to widespread use of stents [6, 9]. 
Although increasingly complex lesions and higher-risk 
patients are being successfully treated percutaneously, reste-
nosis and disease progression continue to cause significant 
morbidity. 
RESTENOSIS 
  Restenosis is the major weakness of PCI and remains a 
main clinical problem while progression of disease at 
untreated sites occurs at rates approaching 7% per year [1]. 
Restenosis usually occurs within three to nine months after 
PCI [3]. PCI restenosis rate without stenting range between 
20% and 65%, depending on the method of follow-up and 
the criteria used to define restenosis [3-9]. Successfully 
dilated total coronary occlusions have a higher rate of 
angiographic restenosis at 6 months than dilated stenoses 
[13, 14]. Coronary angiography is the "gold standard" for 
detecting restenosis, but its invasive character precludes 
application in patients following PCI. Chest pain symptoms 
and non-invasive techniques, such as exercise electrocar-
diography (ECG) testing, have limited clinical significance 
for evaluating the efficacy of PCI and detecting restenosis 
[15].  
  Patients with symptomatic restenosis develop angina 
within four to five months after PCI [16]. Angina developing 
after nine months is usually due to progression of disease at 
another site [17].  
  Chest pain following PCI is a poor indicator of restenosis 
since asymptomatic restenosis occurs in 18% to 59% of 
patients following PCI and in 30% to 58% of patients after 
stenting, while up to 45% of patients developing chest pain 
after PCI do not have angiographic restenosis [16, 18]. 
Restenosis rate is lower after coronary stenting, ranging to an 
average of 20-25%, while it is even lower (less than 10%) 
using drug-eluting stents [9]. On the other hand, current 
recommendations indicate that individuals with a drug-
eluting stent should receive at least 12 months of un-
interrupted dual antiplatelet treatment. Patients' assessment 
should focus on bleeding abnormalities, pre-existing 
disorders that need anticoagulation treatment, and possible 
future surgical procedures, since these factors could all 
contraindicate use of drug-eluting stents [19]. Thus, reste-
nosis remains the Achilles heel of PCI and also a significant 
clinical problem.  
  MPI encounters some difficulties compared to other 
noninvasive tests; because restenosis is a complex biologic 
phenomenon evolving over time and the detection of disease 
by MPI depends on the presence of hemodynamically 
important stenoses (typically at least 50-70% of the diameter 
of the lumen), therefore  accuracy of stress MPI depends 
upon the timing after revascularization [20]. When MPI is 
performed very early after angioplasty or stenting 
(within 24 - 48 hours), it may exhibit defects in the 
absence of stenoses. These early defects may be due to 
abnormal endothelium function which is common after 
angioplasty and may cause transiently impaired coronary 
flow reserve after intervention, while the prognostic 
significance of these defects is uncertain [21]. Some 
authors found that the incidence of restenosis was 52% to 
75% in patients with reversible defects on early (<2 
months after PCI) imaging, compared with an incidence 
of 12% to 17% in those with normal perfusion and thus 
they stated that MPI performed early after PCI could 
predict future restenosis [22]. Others noticed that 
although reversible perfusion defects in the treated vas-
cular territory, within 48 hours of angiographically suc-
cessful PCI were observed in 54% of patients following 
PCI or atherectomy, and in 43% of patients after stenting, 
there was a significant overlap of residual stenosis values 
between patients with and those without perfusion defects 
[23]. In conclusion, authors suggested that endothelial 
dysfunction may be a possible cause of perfusion defect 
following PCI. The use of stents has lowered the rates of 
early post-PCI false positive MPI scans and therefore, in 
cases concerning the adequacy of high-risk angioplasty 
procedure, early stress MPI scans are considered clini-
cally useful and safe nowadays [24]. 
  On the other hand, ECG gated-SPECT MPI has been 
used shortly after PCI in patients with acute myocardial 
infarction, in order to differentiate reversible from persistent 
left ventricular dysfunction and predict left ventricular 
functional recovery and late functional outcome. It has been 
found that greater increase in left ventricular functional 
recovery occurred in patients with a greater number of 
segments with perfusion/thickening mismatch early (3 days) 
after primary PCI, while matched abnormal segments 
showed no improvement in wall motion score 3 months after 
PCI and their extent, as was evaluated in the early stage of 
myocardial infarction, was related to left ventricular ejection 
fraction at 3 months after PCI [25]. 
EVALUATION OF MPI IN DIAGNOSING RESTE-
NOSIS AFTER PCI  
  Although there have been many studies reporting high 
sensitivity and specificity of MPI in detecting restenosis after 
PCI, nevertheless the literature is limited by verification bias 
because MPI and angiography - which is considered the 
“gold standard” evaluation method - were not performed 
simultaneously but sequentially and results from noninvasive 
testing probably influenced the decision to perform angio-
graphy [26]. In such a study, Hecht and colleagues reported 
that SPECT thallium testing, when compared to coronary 
angiography, had a sensitivity and specificity of 96% and 
75% in asymptomatic and 99% and 77% in symptomatic 
patients [27]. However, as previously pointed out, Hecht’s 
patients did not undergo MPI and coronary angiography 
simultaneously but sequentially.  
  In an important meta-analysis of studies published from 
1975 to 2000, Garzon and Eisenberg found a pooled 
sensitivity and specificity of MPI in diagnosing restenosis 
after PCI, of 87% and 78% respectively [28].  
  In one of our previous studies using Tc-99m tetrofosmin 
as the radiotracer, sensitivity, specificity, positive and 
negative predictive value of MPI in detecting restenosis were 
81.3%, 88%, 81.3% and 88%, respectively, whereas for the 
detection of restenosis in specific vessel, the corresponding 
values were 81.3%, 90%, 76.5% and 89.7%, respectively 
[29]. In the same study, improvement in late (6 months) 100    Current Cardiology Reviews, 2010, Vol. 6, No. 2  Georgoulias et al.
  
post-PCI MPI scans had been observed in most patients with 
successful PCI confirmed with coronary angiography (Fig. 
1). In some patients, although there was scan improvement, 
restenosis was found angiographically. Nevertheless, their 
angiograms revealed less severe stenosis of the corres-
ponding vessels than those taken before PCI. Finally it was 
suggested that since MPI might be significantly improved 
irrespective of the presence or absence of restenosis, 
coronary angiography should be performed only in patients 
who do not show scan improvement or in other clinically 
indicated cases [29]. 
  The sensitivity, specificity and accuracy of MPI in 
predicting restenosis after PCI has also been reported. In a 
study using dobutamine 
201Tl MPI, Caner et al. found that 
the method was 76% sensitive, 79% specific, and 77% 
accurate in predicting restenosis, while the positive and 
negative predictive values were 66% and 86%, respectively. 
Sensitivity and specificity related to the vascular territories 
were: 66-69% for the left anterior descending artery (LAD), 
75-100% for the left circumflex artery (LCX) and 83-66% 
for the right coronary artery (RCA), respectively [30]. 
  MPI for the diagnosis of in stent stenosis (ISS) has also 
been examined. The mean sensitivity, specificity, positive 
and negative predictive values and accuracy of MPI were 
95%, 73%, 88%, 89%, and 88% respectively [31].  
  Finally, MPI has high sensitivity and specificity in the 
detection of restenosis after PCI in stenosed coronary grafts. 
In patients with typical angina the reported sensitivity and 
specificity are 84% and 80% respectively, while in patients 
with atypical chest pain or other symptoms the correspon-
ding rates are 70% and 90%, respectively [32]. 
MPI AND STRESS ECG 
  Stress ECG testing, has limited clinical significance for 
evaluating the efficacy of PCI and detecting restenosis. ECG 
is much less sensitive and specific in detecting restenosis 
after PCI compared to MPI, particularly due to the high 
incidence of baseline electrocardiographic abnormalities in 
patients with CAD. Also, the usefulness of exercise ECG in 
patients with partial revascularization is questionable 
because a positive test may result from non-revascularized 
areas. Even in patients with dilation of all the stenosed 
vessels, a positive response may be indicative of disease 
progression rather than restenosis. Nevertheless, the analysis 
of other exercise variables such as functional capacity, chro-
notropic response index, heart-rate recovery and ventricular 
ectopy during recovery, may improve its diagnostic capacity 
and provide important prognostic information [33]. 
 Beygui  et al reported that the sensitivity, specificity and 
accuracy of stress ECG in asymptomatic patients 6 months 
after PCI, has been reported to be 53%, 59% and 57% 
respectively for stress electrocardiography, compared with 
63%, 77% and 72% for MPI in the same group of patients 
[34]. 
PROGNOSIS  
  It seems that the major clinical contribution of MPI in 
patients post PCI is the significant prognostic value of the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Myocardial perfusion SPECT imaging of a 61-years old patient with one-vessel disease (LAD 95%) before (A) and 6 months after (B) LAD PCI, 
demonstrated significant improvement in the apex, anterior wall and septum. 
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method. It has been reported that the detection of ischemia in 
MPI scans can predict recurrent ischemic events in both 
symptomatic and asymptomatic patients [35]. The long-term 
prognostic value of MPI performed late after PCI (i.e., 
beyond the generally accepted 6-month “restenosis 
window”) has been evaluated in several studies. These 
studies showed that the occurrence of cardiac events (death, 
nonfatal infarction, and late revascularization procedures) 
was higher in the presence of myocardial ischemia in the 
MPI, in both symptomatic and asymptomatic patients, while 
the event-free survival curves showed a higher event rate in 
patients with than those without ischemia. The summed 
stress score (SSS) and summed difference score (SDS) were 
independent significant predictors of cardiac events [15, 36-
38].  
 Specifically,  Cottin  et al., studied 152 patients 5 ± 2 
months after stenting with stress-rest thallium SPECT and 
reported a significant worse prognosis of ischemic patients 
compared with non-ischemic (58% had major cardiac events 
or revascularization vs 11%, p< 0.001) [39]. In addition, Ho 
et al., studying the late outcome of a series of 211 patients 
who underwent a SPECT 
201Tl MPI 1-3 years after PTCA, 
reported that the SSS index was significantly associated with 
the end point of cardiac death or myocardial infraction [40]. 
Similarly, Acampa et al., in a study population of 206 
patients who underwent a 
99mTc-MIBI myocardial SPECT 
12-18 months post PCI, found that SSS and SDS were 
significant predictors of cardiac events, while the occurrence 
of cardiac events was higher in the presence of ischemia at 
SPECT in symptomatic and symptom-free patients (both 
p<0.001) [36]. In a larger study, Zellweger et al. evaluated 
356 patients (both symptomatic and asymptomatic) with a 
99mTc-MIBI myocardial SPECT 6 months after stenting and 
follow-up was an average of about 4 years. A higher degree 
of ischemia measured by SDS was associated with a higher 
rate of death, myocardial infarction and repeat revascu-
larization, while SPECT imaging added incremental infor-
mation for the prediction of critical events [41]. Additio-
nally, similar results have been reported by Solodky et al. 
recently [42]. Comparably, Zhang et al studying 318 patients 
who underwent a 
99mTc-MIBI SPECT 10±12 months after 
PCI, reported that SSS was the best independent predictor 
for hard cardiac events (cardiac death or myo-cardial 
infarction) and SDS was the best independent predictor for 
late revascularization (both p<0.001) [15]. Recently, Galassi 
et al., studied 322 consecutive patients with 
99mTc-
tetrofosmin after incomplete revascularization and found that 
nuclear data provided significant incremental prognostic 
value for cardiac events compared with the clinical, exercise 
testing and angiographic findings (p<0.01) [43]. 
  In two recently published studies, we evaluated the long-
term prognostic value of 
99mTc-tetrofosmin myocardial 
gated-SPECT, in asymptomatic patients after coronary artery 
stenting [37, 38]. We included 246 consecutive patients in 
the study, who underwent exercise gated-SPECT myocardial 
imaging 5-7 months after PCI and were followed-up for a 
mean period of 8.3 years (SD=2.9). Cardiovascular death 
and non-fatal myocardial infarction were considered as hard 
cardiac events, while late revascularization procedures as 
soft events. When multiple Cox regression analysis was 
implied, the factors which remained significant in the final 
model for soft events were SSS, SDS, and angina during 
exercise testing [37]. In addition, SSS, SDS and left 
ventricular dilation were independently associated with hard 
cardiac events as defined from the results of multiple 
analysis [37]. However, SSS and SDS were the only inde-
pendent predictors for both hard and soft events. Moreover, 
99mTc-tetrofosmin myocardial gated-SPECT, provided incre-
mental prognostic information, over clinical and exercise test 
data, for the prediction of cardiac events in asymptomatic 
patients after PCI [38]. 
  However, in these studies there is a general agreement 
that chest pain symptoms are of limited value to predict 
future cardiac events [15, 36-38, 42]. In addition, Elhendy et 
al. studying 381 patients 4.5 ± 3.2 years after myocardial 
revascularization (CABG in 201 patients, PCI in 180 
patients) with 
99mTc-tetrofosmin, found a similar incidence 
of hard cardiac events (cardiac death, non fatal myocardial 
infraction) in patients with and without angina before MPI 
[44]. In fact, they submitted that symptoms were not 
predictive of outcome, while an abnormal MPI indicative of 
myocardial ischemia, was independently associated with the 
composite endpoints of hard cardiac events and late 
revascularization, adding significant incremental prognostic 
value to clinical data in the prediction of hard cardiac events 
(p<0.01) [44]. On the contrary, a normal study identifies a 
very low-risk population (no hard cardiac events during 
follow-up), irrespectively of the method of previous revascu-
larization, in whom no further intervention is required. A 
conclusion of the above studies was that the absence of 
symptoms should not be interpreted as an indicator of a low-
risk status, therefore asymptomatic patients should not be 
deferred from MPI stress testing [37, 38, 44]. 
RECOMMENDATIONS FOR MPI 
  Routine stress MPI is not recommended yet in all patients 
after PCI in order to predict cardiac events and especially in 
patients after coronary stenting where the application of 
drug-eluting stents and the use of dual antiplatelet therapy 
have improved patients prognosis [33]. In addition, given the 
high false-positive rate of MPI early (<3 months) after PCI, 
patients who develop chest pain within this time should 
undergo angiography, as well as patients who present typical 
angina, ECG changes or elevated cardiac enzymes 3 to 6 
months after PCI [1, 33]. Patients lacking such charac-
teristics, who develop atypical symptoms, should undergo 
MPI. Although the specificity of MPI 3 to 6 months 
following PCI might be limited, a normal study should 
reliably exclude restenosis. If perfusion is abnormal, angio-
graphy should be considered as the next step. The “ACCF / 
ASNC / ACR / AHA / ASE / SCCT / SCMR / SNM Appro-
priate Use Criteria for Cardiac Radionuclide Imaging” 
(2009), has recommended as “inappropriate” the general 
application of SPECT MPI in the first 2 years post PCI to 
evaluate asymptomatic patients, although such a follow-up is 
recommended as “appropriate” for asymptomatic patients 
after incomplete revascularization, whereas an additional 
revascularization seems feasible [45]. On the other hand, 
since the accuracy and prognostic value of MPI performed 6 
or more months after PCI is significant, it could be recom-
mended that asymptomatic patients and particularly those 
who were also asymptomatic prior the intervention, should 102    Current Cardiology Reviews, 2010, Vol. 6, No. 2  Georgoulias et al.
  
initially be followed clinically and undergo MPI less than 2 
years (probably 6 to 12 months) after PCI, for further risk 
stratification [1, 15, 36 - 39, 41, 44]. Patients with normal 
and low- or intermediate-risk scans (small or medium-sized 
defects of mild-to-moderate severity) can be managed 
conservatively. Patients with high-risk scans (medium-sized 
severe defects, large defects of any severity, or scans 
showing stress-induced left ventricular failure) should 
undergo angiography. Thereafter, asymptomatic patients 
should undergo MPI every 1 to 3 years unless symptoms 
develop, where MPI should be performed sooner [1, 41].  
  MPI is generally indicated in high risk patients who have 
worse long-term prognosis compared to other patients, such 
as diabetic patients in whom silent ischemia occurs 
commonly after angioplasty, patients with heart failure who 
experience major adverse cardiac events more frequently, 
and patients with saphenous vein graft interventions [32, 35, 
46-48]. The occurrence of ischemia in MPI of asymptomatic 
diabetic patients was found to be associated with a high risk 
for repeat interventional procedures although no difference 
in major cardiac events was noticed compared to symp-
tomatic diabetic patients [48].  
CONCLUSION 
  Over the last decades, SPECT MPI has proven an 
invaluable tool for evaluating patients in cardiovascular 
medicine. In addition, PCI procedures are widely used in 
patients with CAD. By assessing myocardial perfusion, 
SPECT imaging aids in diagnosis of CAD and patient risk 
stratification, providing important information on extent of 
myocardium at risk and scar- myocardial viability, disease 
progression, hemodynamic significance of coronary artery 
stenoses (culprit lesions) and myocardial function using 
gated-SPECT technique. Evaluating the aforementioned 
data, nuclear imaging helps in decision about revascu-
larization and is well suited to assess patients after 
intervention. The literature has demonstrated the usefulness 
of nuclear imaging after PCI, providing significant data in 
patients with recurrent symptoms after revascularization, and 
more importantly, providing prognostic information after the 
intervention, independently of symptoms. Chest pain and 
exercise ECG could be considered unhelpful in identifying 
patients at risk after revascularization but MPI is of proven 
value, although there is still debate on whether or not 
myocardial perfusion SPECT should be performed routinely 
and also about the certain time period. As PCI techniques 
expand and evolve, mainly with the increasing use of drug-
eluting stents with low restenosis rate, the role of nuclear 
imaging will require further investigation.  
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